Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma

References

• Jemal A, Thomax A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23–47
   PubMed Web of Science ®Google Scholar
• Escudier B. Advanced renal cell carcinoma: Current and emerging management strategies. Drugs 2007; 67: 1257–64
   PubMedGoogle Scholar
• Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007; 370: 2103–11
   PubMed Web of Science ®Google Scholar
• Chen LK, Hwang SJ, Tsai ST, Luo JC, Lee SD, Chang FY. Glucose intolerance in Chinese patients with chronic hepatitis C. World J Gastroenterol 2003; 9: 505–8
   PubMed Web of Science ®Google Scholar
• Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998; 28: 514–7
   PubMedGoogle Scholar
• Chedin P, Cahen-Varsaux J, Boyer N. Non-insulin-dependent diabetes mellitus developing during interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1996; 125: 521
   PubMedGoogle Scholar
• Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989; 38: 641–7
   PubMedGoogle Scholar
• Foulis AK, Farquharson MA, Meager A. Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987; 2(8573)1423–7
   PubMed Web of Science ®Google Scholar
• Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MachLachlan NJ. Induction of type I diabetes by interferon-alpha in transgenic mice. Science 1993; 260(5116)1942–6
   PubMed Web of Science ®Google Scholar
• Pankewycz OG, Guan JX, Benedict JF. Cytokines as mediators of autoimmune diabetes and diabetic complications. Endocr Rev 1995;16:164–76. (Review)
   PubMed Web of Science ®Google Scholar
• Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26(3 Suppl 1)112S–121
   PubMed Web of Science ®Google Scholar
• Shiba T, Higashi N, Nishimura Y. Hyperglycaemia due to insulin resistance caused by interferon-gamma. Diabet Med 1998; 15: 435–6
   PubMedGoogle Scholar
• Bex A, Mallo H, Kerst M, Haanen J, Horenblas S, de Gast GC. A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunol Immunother 2005; 54: 713–9
   PubMedGoogle Scholar
• Lopes EP, Oliveira PM, Silva AE, Ferraz ML, Costa CH, Miranda W, Dib SA. Exacerbation of type 2 diabetes mellitus during interferon-alpha therapy for chronic hepatitis B. Lancet 1994; 343(8891)244
   PubMedGoogle Scholar
• Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38–47
   PubMed Web of Science ®Google Scholar
• Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283–91
   PubMed Web of Science ®Google Scholar
• Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003; 18: 549–58
   PubMed Web of Science ®Google Scholar
• Sasso FC, Carbonara O, Di Micco P, Coppola L, Torella R, Niglio A. A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy. Br J Clin Pharmacol 2003; 56: 238–9
   PubMedGoogle Scholar
• Cozzolongo R, Betterle C, Fabris P, Paola Albergoni M, Lanzilotta E, Manghisi OG. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006; 18: 689–92
   PubMed Web of Science ®Google Scholar
• Betterle C, Fabris P, Zanchetta R, Pedini B, Tositti G, Bosi E, de Lalla F. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000; 23: 1177–81
   PubMed Web of Science ®Google Scholar